Intuitive Surgical is in a sustained downtrend, with the stock down 22.7% over the past year and currently trading at 67.3% of its 52-week range (price $406.78 vs. 52-week high $603.88 and low $396.68). The price sits near the low end of the range, suggesting a potential value opportunity but also reflecting persistent selling pressure and bearish sentiment. The 1-year price change of -22.7% contrasts sharply with the S&P 500's +20.6% gain, indicating significant relative weakness. Short-term momentum remains negative but shows signs of stabilization: the 1-month change is -1.3% and the 3-month change is -9.7%, both still negative but less severe than the 6-month decline of -30.6%. This deceleration in the rate of decline could hint at a potential bottoming process, though the stock has not yet confirmed a reversal. The relative strength versus the S&P 500 is deeply negative across all timeframes, with a 1-month relative strength of -5.3% and a 1-year relative strength of -43.3%, underscoring persistent underperformance. Key support is at the 52-week low of $396.68, a break below which could trigger further downside toward $380. Resistance is at the 52-week high of $603.88, and a breakout above that level would signal a major trend reversal. The stock's beta of 1.46 indicates it is 46% more volatile than the market, meaning amplified moves in both directions, which is critical for risk management.

Revenue growth is robust and accelerating: Q4 2025 revenue of $2.866 billion grew 18.8% year-over-year, up from 18.1% in Q3 2025 and 15.0% in Q2 2025. The revenue trajectory is clearly accelerating, driven by strong demand for instruments and accessories ($1.658 billion) and systems ($786 million), which together account for 85% of total revenue. Services revenue of $422 million provides a stable recurring base. This growth acceleration supports the investment case for a company benefiting from increasing adoption of robotic surgery globally. Profitability is excellent: net income for Q4 2025 was $794.8 million, with a net margin of 27.7%, while gross margin was 66.4%. Operating margin improved to 30.2% in Q4 2025 from 25.7% in Q1 2025, showing margin expansion as revenue scales. The company is solidly profitable with a trailing PE of 70.8x, but the high margins are typical for a medical device leader with a dominant installed base. The balance sheet is fortress-like: debt-to-equity is just 0.017, indicating virtually no leverage, and the current ratio is 4.87, reflecting ample liquidity. Free cash flow for Q4 2025 was $730 million, and trailing twelve-month FCF was $2.49 billion, providing strong internal funding for growth. ROE of 16.0% and ROA of 10.2% demonstrate efficient capital use, though the high FCF yield of 1.2% (based on market cap) is modest due to the premium valuation.